Weekly Research Analysts’ Ratings Changes for IDEXX Laboratories (IDXX)

A number of firms have modified their ratings and price targets on shares of IDEXX Laboratories (NASDAQ: IDXX) recently:

• 12/22/2025 – IDEXX Laboratories was downgraded by analysts at Weiss Ratings from a “buy (b-)” rating to a “hold (c+)” rating.
• 12/15/2025 – IDEXX Laboratories had its “buy (b-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/8/2025 – IDEXX Laboratories is now covered by analysts at Barclays PLC. They set an “overweight” rating and a $850.00 price target on the stock.
• 12/8/2025 – IDEXX Laboratories had its “buy (b-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/8/2025 – IDEXX Laboratories is now covered by analysts at Barclays PLC. They set an “overweight” rating and a $850.00 price target on the stock.
• 12/1/2025 – IDEXX Laboratories was upgraded by analysts at Weiss Ratings from a “hold (c+)” rating to a “buy (b-)” rating.
• 11/29/2025 – IDEXX Laboratories was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.
• 11/25/2025 – IDEXX Laboratories had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/19/2025 – IDEXX Laboratories had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/16/2025 – IDEXX Laboratories was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 11/13/2025 – IDEXX Laboratories was downgraded by analysts at Weiss Ratings from a “buy (b-)” rating to a “hold (c+)” rating.
• 11/8/2025 – IDEXX Laboratories was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 11/4/2025 – IDEXX Laboratories had its price target raised by analysts at Morgan Stanley from $765.00 to $805.00. They now have an “overweight” rating on the stock.
• 11/4/2025 – IDEXX Laboratories had its price target raised by analysts at UBS Group AG from $710.00 to $750.00. They now have a “neutral” rating on the stock.
• 11/4/2025 – IDEXX Laboratories had its price target raised by analysts at BTIG Research from $785.00 to $830.00. They now have a “buy” rating on the stock.
• 11/4/2025 – IDEXX Laboratories had its “buy” rating reaffirmed by analysts at Jefferies Financial Group Inc.. They now have a $830.00 price target on the stock.
• 11/4/2025 – IDEXX Laboratories had its price target raised by analysts at JPMorgan Chase & Co. from $675.00 to $775.00. They now have an “overweight” rating on the stock.
• 11/3/2025 – IDEXX Laboratories was given a new $785.00 price target on by analysts at Leerink Partners.
• 11/3/2025 – IDEXX Laboratories was given a new $775.00 price target on by analysts at Stifel Nicolaus.
• 10/31/2025 – IDEXX Laboratories was upgraded by analysts at Stifel Nicolaus from a “hold” rating to a “buy” rating. They now have a $700.00 price target on the stock, up previously from $640.00.

Insider Buying and Selling

In related news, EVP Nimrata Hunt sold 9,425 shares of the company’s stock in a transaction on Friday, November 7th. The stock was sold at an average price of $703.34, for a total transaction of $6,628,979.50. Following the completion of the sale, the executive vice president owned 21,149 shares in the company, valued at approximately $14,874,937.66. This represents a 30.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.98% of the company’s stock.

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.